Search

Your search keyword '"Kulalert, Prapasri"' showing total 20 results
Start Over Author "Kulalert, Prapasri" Search Limiters Full Text
20 results on '"Kulalert, Prapasri"'

8. Development and validation of a practical score to predict 3-year distant metastatic free survival in nasopharyngeal carcinoma incorporating the number of lymph node regions.

Author

Jaruthien, Thitiporn, Lertbutsayanukul, Chawalit, Jittapiromsak, Nutchawan, Sriyook, Aniwat, Kulalert, Prapasri, Tantiyavarong, Pichaya, Kitpanit, Sarin, Kannarunimit, Danita, Chakkabat, Chakkapong, and Prayongrat, Anussara

Subjects
NASOPHARYNX cancer, PROGNOSTIC models, LYMPH nodes, SURVIVAL analysis (Biometry), METASTASIS
Abstract

Introduction: The improvement in diagnosis and treatment for nasopharyngeal carcinoma (NPC) has shifted the pattern of failure toward distant metastasis. This study aimed to develop a simplified prognostic scoring model to predict distant metastatic free survival (DMFS) for NPC patients. Materials and methods: Patients with non-metastatic NPC were identified from a retrospective cohort diagnosed between 2010 and 2018. Flexible parametric survival analysis was used to identify potential predictors for DMFS and establish a scoring model. The prognostic accuracy between the 8th AJCC system and the scoring model was compared using Harrell's C-index. Results: Of the total 393 patients, the median follow-up time was 85 months. The 3-year DMFS rate was 83.3%. Gender, T-stage, pre-EBV (cut-off 2300 copies/ml), and the number of metastatic lymph node regions were identified as independent risk factors for distant metastasis and were included in the final scoring model. Our established model achieved a high C-index in predicting DMFS (0.79) and was well-calibrated. The score divided patients into two categories: low-risk (score 0–4) and high-risk (score 5–7), corresponding with the predicted 3-year DMFS of 96% and 64.5%, respectively. Conclusions: A feasible and applicative prognostic score was established and validated to discriminate NPC patients into low- and high-risk groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival

Author

Warnnissorn, Naree, primary, Kanitsap, Nonglak, additional, Niparuck, Pimjai, additional, Boonsakan, Paisarn, additional, Kulalert, Prapasri, additional, Limvorapitak, Wasithep, additional, Bhoopat, Lantarima, additional, Saengboon, Supawee, additional, Chantrathammachart, Pichika, additional, Puavilai, Teeraya, additional, and Chuncharunee, Suporn, additional

Published
2022
Full Text
View/download PDF

15. Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation

Author

Kulalert,Prapasri, Phinyo,Phichayut, Patumanond,Jayanton, Smathakanee,Chutima, Chuenjit,Wantida, and Nanthapisal,Sira

Subjects
Journal of Asthma and Allergy
Abstract

Prapasri Kulalert,1 Phichayut Phinyo,2,3 Jayanton Patumanond,3 Chutima Smathakanee,4 Wantida Chuenjit,4 Sira Nanthapisal5 1Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand; 2Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 3Center for Clinical Epidemiology and Clinical Statistics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4Department of Pediatrics, Hat Yai Hospital, Songkhla, Thailand; 5Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, ThailandCorrespondence: Phichayut PhinyoDepartment of Family Medicine, Faculty of Medicine, Chiang Mai University, 110/510 Intawaroros Road, Suthep, Mueang Chiang Mai District, Chiang Mai, Chiang Mai Province 50200, ThailandTel +66 89 850 1987Email phichayutphinyo@gmail.comPurpose: Intermittent nebulization of short-acting beta-agonists (SABA) is the initial treatment of choice for children with asthma exacerbation. However, children with severe asthma exacerbation (SAE) may not show an adequate response and need aggressive stepwise therapy. We aimed to explore factors associated with a poor response to intermittent nebulized SABA in children with SAE.Methods: A retrospective cohort study of children with SAE diagnosed according to the definition of the British Guidelines on the Management of Asthma, who were admitted at Hat Yai Hospital from January 1, 2015, to December 31, 2017. All children were treated with intermittent SABA nebulization. Treatment failure was defined as children needing escalated therapy. Logistic regression with confounding score adjustment was used to explore the predictors of treatment failure.Results: One hundred thirty-three children were included in the analysis, 59 were in the failure group and 74 were in the success group. After adjusting for potential confounders, they were significantly associated with a previous history of intubation (adjusted OR 6.46, 95% CI 1.13 to 36.79, p=0.036), receiving < 3 doses of nebulized salbutamol in the emergency room (ER, aOR 3.21, 95% CI 1.15 to 9.02, p=0.027), ER measured oxygen saturation (SpO2) < 92% (adjusted OR 3.02, 95% CI 1.18 to 7.75, p=0.022), and exacerbation triggered by pneumonia (adjusted OR 2.67, 95% CI 1.19 to 6.00, p=0.017).Conclusion: We identified four prognostic factors of treatment failure in children with SAE: a previous history of intubation; receiving < 3 doses of nebulized salbutamol in the ER, SpO2 at ER < 92%; and exacerbation triggered by pneumonia. Further prospective studies are required to confirm our findings before clinical implementation.Keywords: status asthmaticus, hospitalization, nebulization, treatment failure, prognosis

Published
2020

16. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects: Rome, Italy/Vatican City. 27-29 April 2017

Author

Traina, Giovanni, Valluzzi, Rocco Luigi, Fierro, Vincenzo, Riccardi, Carla, Artesani, Maria Cristina, De Vuono, Andrea, Fiocchi, Alessandro, Martelli, Alberto G, Ríos, Luis Alberto, Alcocer, Christian R, Navarrete, Elsy, Del Rio Navarro, Blanca Estela, Gonzalez, Victor, Velasco, Berenice, Perez Aviles, Herberth J, Fernandez, Roberto Jose, Pozo, F Cesar, Farhan, Abdal Jabbar, Arshad, Hasan, Hussain, Ahmed, Sharikadze, Olena, Okhotnikova, Olena, Alcover, Javier, Rodriguez, Diego, Pineda, Fernando, Dalal, Ilan, Weinbrand-Goichberg, Jenny, Benor, Shira, Rottem, Menachem, Kivity, Shmuel, Sato, Sakura, Yanagida, Noriyuki, Ebisawa, Motohiro, Umanets, Tetiana, Antipkin, Youriy, Barzylovich, Vladyslava, Lapshyn, Volodymyr, Umanets, Mykola, Yuriev, Sergey, Bekir, Suzan, Pincock, Tobias, Vieira Hernandez, Alberto, Capriles Hulett, Arnaldo, Sánchez Borges, Mario, Fabiano, Fabiola, Albarran, Carlos, Goyal, Rohit, Gupta, Shilpa, Gaurav, Garg, Luskin, Allan T, Griffin, Noelle M, Wagelie-Steffen, Amy, Trzaskoma, Benjamin L, Limb, Susan L, Busse, William W, Zeiger, Robert S, Gonzalez-Reyes, Erika, Casale, Thomas B, Chipps, Bradley E, Sugizaki, Chizuko, Goto, Fumiko, Yamaide, Akiko, Mitsunaga, Kanako, Tomiita, Minako, Hoshioka, Akira, Shimojo, Naoki, Pop, Liviu L, Ciucǎ, Ioana-Mihaela, Tǎmaş, Liviu, Lazarescu, Marilena, Pienar, Corina, Yamaide, Fumiya, Fikri, Bahrul, Sato, Hironori, Okishima, Naoko, Kobayashi, Miyabi, Takai, Mizuki, Nishigata, Kotarou, Yoda, Ryou, Oana, Yu-Ta, Kajiwara, Chifu, Shimodaira, Moe, Suzuki, Tomoka, Iizawa, Hiromi, Kamijo, Koji, Karmakar, Bijoya, Bhattacharya, Swati Gupta, Blohlávková, Simona, Kopelentová, Eliška, Víšek, Petr, Štádler, Jakub, Šetinová, Ivana, Novobílská, Jana, Lundelin, Krisa, Salminen, Seppo, Isolauri, Erika, Pitt, Tracy, Flanders, Tamar, Peñalver, Marcos, Martínez, Patricia, Lluch, Magdalena, Malet, Alfonso, Nam, Young-Hee, Jin, Hyun Jung, Lee, Soo-Keol, Kulalert, Prapasri, Sritipsukho, Paskorn, Pathumanond, Jayanton, Baynova, Krasimira, Labella, Marina, De Aramburu, Teresa, Prados, Manuel, Haanpää, Leena, Aarnio, Jasmin, Nermes, Merja, Af Ursin, Piia, Kaljonen, Anne, Bala, Nandana, Bhagwat, Ketaki, Hindley, James, Chapman, Martin, Baalasubramanian, Sivasankar, Besednjak-Kocijančič, Lilijana, SenGupta, Koyel, Antonova, Evgeniya, Kong, Amanda M, Iqbal, Ahmar, Teague, W Gerald, Trzaskoma, Benjamin, Ortiz, Benjamin, Paknis, Brandee, Iqbal, Amar, Rosen, Karin, Szefler, Stanley, Alblooshi, Afaf, Al-Hammadi, Suleiman, Vega, Arantza, Gutiérrez-Rivas, Raquel, Alonso, Ana Maria, Beitia, Juan Maria, Belén Mateo, Maria, Cárdenas, Remedios, García-Domínguez, Juan Jesús, Pitchon Dos Reis, Raquel, Gonçalves Alvim, Cristina, Andrade, Claudia, Reis, Adriana, Ribeiro, Henrique, Panaitescu Bunu, Carmen, Marusciac, Laura, Paralescu, Sorin, Tamas, Paul, Panitescu Bunu, Carmen, Martí Guadaño, Enrique, Escobar Bolaños, Carolina, Martí José, Natalia, Pau Casanovas, Pol, Biarnés Rib, Gemma, Castells, Mariana, de Vicente Jiménez, Talía, Mennini, Maurizio, De Angelis, Papola, Rea, Francesca, Malamisura, Monica, Tambucci, Renato, Dall'Oglio, Luigi, Del Chierico, Federica, Napolitano, Tania, Reddel, Silvia, Vernocchi, Pamela, D'Ambrosio, Angelo, Putignani, Lorenza, Dahdah, Lamia, Banzato, Claudia, Echeverría Zudaire, Luís Angel, Plaza, Ana María, Bosque García, Montserrat, Íbero, Marcel, Mazzina, Oscar, Marzano, Valeria, Pecora, Valeria, Koch, Pierluigi, Pecora, Valentina, Valentini, Diletta, Santamaria, Francesca, Valluzzi, Rocco, Mukherjee, Anwesha, Kandhare, Amit, and Bodhankar, Subhash

Published
2017

17. Proceedings of the 2017 WAO Symposium on Hot Topics in Allergy: Pediatric & Regulatory Aspects

Author

Traina, Giovanni, Valluzzi, Rocco Luigi, Fierro, Vincenzo, Riccardi, Carla, Artesani, Maria Cristina, De Vuono, Andrea, Fiocchi, Alessandro, Martelli, Alberto G., Ríos, Luis Alberto, Alcocer, Christian R., Navarrete, Elsy, Del Rio Navarro, Blanca Estela, Gonzalez, Victor, Velasco, Berenice, Perez Aviles, Herberth J., Fernandez, Roberto Jose, Pozo, F. Cesar, Farhan, Abdal Jabbar, Arshad, Hasan, Hussain, Ahmed, Sharikadze, Olena, Okhotnikova, Olena, Alcover, Javier, Rodriguez, Diego, Pineda, Fernando, Dalal, Ilan, Weinbrand-Goichberg, Jenny, Benor, Shira, Rottem, Menachem, Kivity, Shmuel, Sato, Sakura, Yanagida, Noriyuki, Ebisawa, Motohiro, Umanets, Tetiana, Antipkin, Youriy, Barzylovich, Vladyslava, Lapshyn, Volodymyr, Umanets, Mykola, Yuriev, Sergey, Bekir, Suzan, Pincock, Tobias, Vieira Hernandez, Alberto, Capriles Hulett, Arnaldo, Sánchez Borges, Mario, Fabiano, Fabiola, Albarran, Carlos, Goyal, Rohit, Gupta, Shilpa, Gaurav, Garg, Luskin, Allan T., Griffin, Noelle M., Wagelie-Steffen, Amy, Trzaskoma, Benjamin L., Limb, Susan L., Busse, William W., Zeiger, Robert S., Gonzalez-Reyes, Erika, Casale, Thomas, Chipps, Bradley E., Sugizaki, Chizuko, Goto, Fumiko, Yamaide, Akiko, Mitsunaga, Kanako, Tomiita, Minako, Hoshioka, Akira, Shimojo, Naoki, Pop, Liviu L., Ciucǎ, Ioana-Mihaela, Tǎmaş, Liviu, Lazarescu, Marilena, Pienar, Corina, Yamaide, Fumiya, Fikri, Bahrul, Sato, Hironori, Okishima, Naoko, Kobayashi, Miyabi, Takai, Mizuki, Nishigata, Kotarou, Yoda, Ryou, Oana, Yu-ta, Kajiwara, Chifu, Shimodaira, Moe, Suzuki, Tomoka, Iizawa, Hiromi, Kamijo, Koji, Karmakar, Bijoya, Bhattacharya, Swati Gupta, Blohlávková, Simona, Kopelentová, Eliška, Víšek, Petr, Štádler, Jakub, Šetinová, Ivana, Novobílská, Jana, Lundelin, Krisa, Salminen, Seppo, Isolauri, Erika, Pitt, Tracy, Flanders, Tamar, Peñalver, Marcos, Martínez, Patricia, Lluch, Magdalena, Malet, Alfonso, Nam, Young-Hee, Jin, Hyun Jung, Lee, Soo-Keol, Kulalert, Prapasri, Sritipsukho, Paskorn, Pathumanond, Jayanton, Baynova, Krasimira, Labella, Marina, De Aramburu, Teresa, Prados, Manuel, Haanpää, Leena, Aarnio, Jasmin, Nermes, Merja, af Ursin, Piia, Kaljonen, Anne, Bala, Nandana, Bhagwat, Ketaki, Hindley, James, Chapman, Martin, Baalasubramanian, Sivasankar, Besednjak-Kocijančič, Lilijana, SenGupta, Koyel, Antonova, Evgeniya, Kong, Amanda M., Iqbal, Ahmar, Teague, W. Gerald, Trzaskoma, Benjamin, Ortiz, Benjamin, Paknis, Brandee, Iqbal, Amar, Rosen, Karin, Szefler, Stanley, Alblooshi, Afaf, Al-Hammadi, Suleiman, Vega, Arantza, Gutiérrez-Rivas, Raquel, Alonso, Ana Maria, Beitia, Juan Maria, Belén Mateo, Maria, Cárdenas, Remedios, García-Domínguez, Juan Jesús, Pitchon dos Reis, Raquel, Gonçalves Alvim, Cristina, Andrade, Claudia, Reis, Adriana, Ribeiro, Henrique, Panaitescu Bunu, Carmen, Marusciac, Laura, Paralescu, Sorin, Tamas, Paul, Panitescu Bunu, Carmen, Martí Guadaño, Enrique, Escobar Bolaños, Carolina, Martí José, Natalia, Pau Casanovas, Pol, Biarnés Rib, Gemma, Castells, Mariana, de Vicente Jiménez, Talía, Mennini, Maurizio, De Angelis, Papola, Rea, Francesca, Malamisura, Monica, Tambucci, Renato, Dall'Oglio, Luigi, Del Chierico, Federica, Napolitano, Tania, Reddel, Silvia, Vernocchi, Pamela, D'Ambrosio, Angelo, Putignani, Lorenza, Dahdah, Lamia, Banzato, Claudia, Echeverría Zudaire, Luís Angel, Plaza, Ana María, Bosque, Montserrat, Íbero, Marcel, Mazzina, Oscar, Marzano, Valeria, Pecora, Valeria, Koch, Pierluigi, Pecora, Valentina, Valentini, Diletta, Santamaria, Francesca, Mukherjee, Anwesha, Kandhare, Amit, Bodhankar, Subhash, and Universitat Autònoma de Barcelona

Subjects
lcsh:Immunologic diseases. Allergy, Pulmonary and Respiratory Medicine, business.industry, Immunology, MEDLINE, Library science, Meeting Abstracts, Vatican City, Hot topics, Immunology and Allergy, Medicine, lcsh:RC581-607, business
Published
2017

18. Inhibitory effect of Zingiber cassumunar Roxb. (Phlai) on nasal cytokine productions and eosinophilic recruitment in patients with allergic rhinitis.

Author

Achararit N, Tharabenjasin P, Kulalert P, Sritipsukho P, Nanthapisal S, Pabalan N, Krishnamra N, Suntornsaratoon P, and Poachanukoon O

Subjects
Humans, Cross-Over Studies, Interleukin-5 therapeutic use, Nasal Mucosa, Cytokines, Interleukin-13, Rhinitis, Allergic diagnosis, Rhinitis, Allergic drug therapy
Abstract

Background: Zingiber cassumunar Roxb. (Phlai) has been used for the treatment of allergies including allergic rhinitis (AR). Although the anti-histamine effects have been reported, assessment of nasal cytokine and eosinophil production had not been investigated., Objective: This study aimed to examine the effect of Phlai on alterations in nasal pro-inflammatory cytokine levels and eosinophil counts in nasal mucosa., Methods: This was a randomized, double-blind, three-way crossover study. Nasal concentrations of cytokines, namely interleukin (IL)-4, IL-5, IL-13 and interferron-gamma (IFN-γ), nasal smear eosinophilia as well as total nasal symptom score (TNSS) were evaluated before and after a 4 weeks treatment with 200 mg Phlai capsules or placebo in 30 AR patients., Results: We observed significant (p < 0.05) reduction in IL-5, IL-13 as well as the number of eosinophils in subjects given Phlai. The degree of improvement of TNSS after Phlai treatment was initially manifested in week 2 with the greatest effect in week 4. In contrast, there were no significant differences in all nasal cytokines, eosinophil counts or TNSS between before and after receiving placebo., Conclusions: These findings provided the first evidence for the anti-allergic effect of Phlai which possibly involved inhibition of nasal pro-inflammatory cytokines production and eosinophilic recruitment. Phlai thus represents a promising herbal medicine for alleviating inflammation and AR symptoms.

Published
2024
Full Text
View/download PDF

19. Factor associated with food allergy among preschool children with atopic dermatitis, and resolution of atopic dermatitis.

Author

Tangvalelerd S, Kanchanapoomi K, Kulalert P, Pacharn P, Jirapongsananuruk O, Visitsunthorn N, Nitiyarom R, Wisuthsarewong W, and Srisuwatchari W

Abstract

Background: Food allergy (FA) has been reported in one-third of children with moderate-to-severe atopic dermatitis (AD)., Objective: To identify factor associated with food allergy among preschool children with AD, and to compare AD resolution between preschool children with and without FA., Methods: A cross-sectional study using database registry and questionnaire interview was conducted at Siriraj Hospital(Bangkok, Thailand) during 2022, and physician-diagnosed AD children aged ≤ 6 years were enrolled., Results: A total of 110 children (60.9% male, median age: 2.3 years) were included. Of those, 53 and 57 children had AD with and without FA, respectively. Very early-onset AD (≤ 3 months) and moderate-to-severe AD at onset were reported in 43.9% and 26.3% of AD without FA, and in 35.8% and 45.3% of AD with FA, respectively. The most commonly reported FAs were hen's egg, cow's milk, and wheat. Moderate-to-severe AD at onset was found significant associated with FA (aOR: 2.50; p = 0.037). Thirty-one (28.2%) patients experienced completed resolution of AD by 5 years of age. Of those, 19 had AD without FA, and 12 had AD with FA (p = 0.213). The median age at AD resolution was 18 months and 22.5 months in the without and with FA groups, respectively. AD with FA showed a strong trend toward a significantly longer duration to achieving AD resolution after adjusting for onset and severity of AD (aHR: 0.46, p = 0.050)., Conclusion: Preschool AD children with FA were found to have significantly greater AD severity at AD onset and a longer duration to AD resolution compared to AD children without FA.

Published
2024
Full Text
View/download PDF

20. Efficacy, patients' perception, and cost of medication in allergic rhinitis with subcutaneous immunotherapy.

Author

Thanborisutkul K, Khodtecha N, Kulalert P, and Sritipsukho P

Subjects
Humans, Cross-Sectional Studies, Injections, Subcutaneous, Allergens, Desensitization, Immunologic adverse effects, Immunotherapy, Perception, Quality of Life, Rhinitis, Allergic therapy
Abstract

Background: Allergic rhinitis (AR) is the allergic inflammation of nasal mucosa. Treatment of AR includes pharmacotherapy and allergen immunotherapy. Subcutaneous immunotherapy (SCIT) is indicated in inadequate disease control, patient's preference, or impossible allergen avoidance. SCIT is an effective treatment but its cost is comparatively high. Efficacy, patient perception, and cost of medication are rarely explored in Asia., Objective: To study efficacy, patient perception, and cost-benefit of SCIT in AR., Methods: We performed a descriptive cross-sectional study at Thammasat University Hospital, Thailand. AR patients who had been receiving SCIT were interview. Current and recall of AR total symptom score (TSS), quality of life, and perception were scored. Cost of medications before SCIT and current cost were reviewed from the medical records., Results: A total of 142 patients were enrolled. Sixty-eight patients (47.9%) received single allergen; house dust mite was the most common allergen. The median of maintenance phase was 47 months, range 15-142 months. The mean of current TSS was significantly lower than mean TSS before SCIT. Forty-two patients (29.6%) had discontinued SCIT on the day of the interview. After discontinuation of SCIT, TSS was still lower than TSS before SCIT. The average cost of medications including SCIT was lower than that of before SCIT with an average difference of 254.2 USD/year. Sixteen patients (11.3%) experienced systemic reaction, 8 of which had reaction during rush immunotherapy., Conclusions: SCIT is an effective, cost-saving and safe treatment option for AR. Rush immunotherapy can reduce duration of build-up phase but increase the risk of systemic reaction.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results